Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid-free vs Opioid-based Analgesia in Thoracoscopic Lobectomy
NCT06570538Phase 1Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of ropivacaine in postoperative pain (2 arms), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Postoperative analgesic efficacy at cough at 48 hours. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06570538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570538.